Public Health Outcomes May Differ After Switching from Brand-Name to Generic Angiotensin II Receptor Blockers

• Үндсэн зохиолчид: Jacinthe Leclerc (Зохиогч), Claudia Blais (Зохиогч), Louis Rochette (Зохиогч), Denis Hamel (Зохиогч), Line Guénette (Зохиогч), Claudia Beaudoin (Зохиогч), Paul Poirier (Зохиогч)
• Формат: Ном
• Хэвлэсэн: Adis, Springer Healthcare, 2020-04-01T00:00:00Z.
• Нөхцлүүд: article
• Онлайн хандалт: Connect to this object online.

Abstract Background It is unclear whether generics are as safe as brand-name drugs in cardiology. For public health surveillance purposes, we evaluated if switching from the brand-name losartan, valsartan, or candesartan impacted the occurrence of the following outcomes: emergency room (ER) consulta...